Prolyl-Hydroxylase Inhibitors
"Prolyl-Hydroxylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the action of HYDROXYLASES that act on PROLINE to form HYDROXYPROLINE.
| Descriptor ID |
D064800
|
| MeSH Number(s) |
D27.505.519.389.740
|
| Concept/Terms |
Prolyl-Hydroxylase Inhibitors- Prolyl-Hydroxylase Inhibitors
- Inhibitors, Prolyl-Hydroxylase
- Prolyl Hydroxylase Inhibitors
- Proline Dioxygenase Inhibitors
- Dioxygenase Inhibitors, Proline
- Inhibitors, Proline Dioxygenase
- Proline Hydroxylase Inhibitors
- Hydroxylase Inhibitors, Proline
- Inhibitors, Proline Hydroxylase
|
Below are MeSH descriptors whose meaning is more general than "Prolyl-Hydroxylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Prolyl-Hydroxylase Inhibitors".
This graph shows the total number of publications written about "Prolyl-Hydroxylase Inhibitors" by people in this website by year, and whether "Prolyl-Hydroxylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 |
| 2021 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prolyl-Hydroxylase Inhibitors" by people in Profiles.
-
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 10; 104(4):655-680.
-
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
-
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
-
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 06; 99(6):1280-1295.
-
Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep. 2020 06; 8(11):e14434.
-
Reducing radiation-induced gastrointestinal toxicity - the role of the PHD/HIF axis. J Clin Invest. 2016 10 03; 126(10):3708-3715.
-
PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2. Sci Transl Med. 2014 May 14; 6(236):236ra64.